Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

AVI BioPharma, Inc., a developer of RNA–based drugs, announced the signing of an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application related to the treatment of Duchenne Muscular Dystrophy (DMD).


Previous Article Next Article

Today in M&A/Partnerships...keeping you current

New graduate degree offered focusing on health care quality
National Committee for Quality Assurance (NCQA), 06/11/09

GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
PharmExec, 06/04/09

Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibody
Sanofi-aventis, 05/15/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address